Latest News

Libigel late stage trials proved disappointing when it did not meet its primary or secondary endpoints relating to an increase in satisfaction and desire in postmenopausal women...

Apricus Biosciences is finally ready to market their erectile dysfunction treatment, Vitaros this November in Canada...

Biosante Pharmacueticals, who are running phase III trials for the latest hopeful in HSDD (hypoactive sexual desire disorder), Libigel ( testosterone gel) have now completed the recruitment part of their trial and now may commence the study which will observe the safety and efficacy of this treatmen...

On and on goes the debate about whether or not Hypoactive Sexual Desire Disorder (HSDD) can be addressed as a physiological disorder...

The European Medicines Agency (EMA) has been informed that Warner Chilcott UK Ltd has withdrawn its application which sought to extend the treatment scope of the hormonal patch, Intrinsa...